Research advancements and evaluation of multifactor-induced murine models for gastric cancer

Abstract

As one of the most prevalent gastrointestinal malignancies in humans, gastric cancer (GC) is often detected at an advanced stage, resulting in a poor prognosis and ranking it the fifth leading cause of cancer-related deaths. Due to their high genomic correlation with humans, mice are ideal in vivo models for investigating GC-related pathogenesis and therapeutic interventions. This review provides an overview of different GC models, including genetically engineered, transplantation-based models, and chemically or biologically induced models, and discusses the recent advancements for each type, highlighting their unique contributions to the field. In addition, it summarizes the strengths, limitations, and typical applications of these models and offers a critical assessment of their applicability in research while acknowledging their current limitations in fully mirroring human GC progression. Furthermore, we analyze how each model accurately recapitulates the complexities of human GC and evaluate their potential for clinical translation. This review provides a reference for model selection in future GC research.

Keywords

gastric cancer mouse model / gastrointestinal malignancy / Helicobacter pylori / patient-derived xenograft

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.

[2] Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330-1344.

[3] Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.

[4] Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.

[5] Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: a global perspective. J Gastroenterol Hepatol. 2020;35(9):1495-1502.

[6] Kim J, Cho YA, Choi WJ, Jeong SH. Gene-diet interactions in gastric cancer risk: a systematic review. World J Gastroenterol. 2014;20(28):9600-9610.

[7] Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429.

[8] Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735-6740.

[9] Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622-628.

[10] Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.

[11] Zhang XY, Zhang PY. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2017;54(5):305-312.

[12] Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc. 2014;47(6):478-489.

[13] Rao X, Zhang C, Luo H, et al. Targeting gastric cancer stem cells to enhance treatment response. Cells. 2022;11(18):2828.

[14] Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature. 2002;420(6915):520-562.

[15] Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA, Solovyeva VV. Mouse tumor models for advanced cancer immunotherapy. Int J Mol Sci. 2020;21(11):4118.

[16] Dunbar AJ, Bowman RL, Park YC, et al. Jak2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms. Cancer Discov. 2024;14(5):737-751.

[17] Regua AT, Arrigo A, Doheny D, Wong GL, Lo HW. Transgenic mouse models of breast cancer. Cancer Lett. 2021;516:73-83.

[18] Leibold J, Tsanov KM, Amor C, et al. Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nat Can. 2024;5(2):315-329.

[19] Duan S, Rico K, Merchant JL. Gastrin: from physiology to gastrointestinal malignancies. Function (Oxf). 2022;3(1):zqab062.

[20] Wang TC, Bonner-Weir S, Oates PS, et al. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J Clin Invest. 1993;92(3):1349-1356.

[21] Wang TC, Brand SJ. Function and regulation of gastrin in transgenic mice: a review. Yale J Biol Med. 1992;65(6):705-713; discussion 737–40.

[22] Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000;118(1):36-47.

[23] Pinzon-Guzman C, Meyer AR, Wise R, et al. Evaluation of lineage changes in the gastric mucosa following infection with Helicobacter pylori and specified intestinal Flora in INS-GAS mice. J Histochem Cytochem. 2019;67(1):53-63.

[24] Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020;11(5):1220-1230.

[25] Brembeck FH, Schreiber FS, Deramaudt TB, et al. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 2003;63(9):2005-2009.

[26] Soutto M, Belkhiri A, Piazuelo MB, et al. Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 2011;121(5):1753-1767.

[27] Zhang S, Kim W, Pham TT, Rogers AB, Houghton JM, Moss SF. Native and bone marrow-derived cell mosaicism in gastric carcinoma in H. pylori-infected p27-deficient mice. Oncotarget. 2016;7(43):69136-69148.

[28] Okumura T, Ericksen RE, Takaishi S, et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res. 2010;70(21):8435-8445.

[29] Fatehullah A, Terakado Y, Sagiraju S, et al. A tumour-resident Lgr5(+) stem-cell-like pool drives the establishment and progression of advanced gastric cancers. Nat Cell Biol. 2021;23(12):1299-1313.

[30] Kim W, Chu TH, Nienhüser H, et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology. 2021;160(3):781-796.

[31] Putoczki TL, Thiem S, Loving A, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013;24(2):257-271.

[32] Won Y, Choi E. Mouse models of Kras activation in gastric cancer. Exp Mol Med. 2022;54(11):1793-1798.

[33] Seidlitz T, Chen YT, Uhlemann H, et al. Mouse models of human gastric cancer subtypes with stomach-specific CreERT2-mediated pathway alterations. Gastroenterology. 2019;157(6):1599-1614. e2.

[34] Shimada S, Mimata A, Sekine M, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012;61(3):344-353.

[35] Liu Y, Jiang Z, Yang H, et al. Tea extracts inhibit gastric cancer growth in vitro and in vivo and prolong survival in nude mice. Front Biosci Landmark Ed. 2022;27(8):250.

[36] Tu L, Zhao E, Zhao W, et al. hsa-miR-376c-3p regulates gastric tumor growth both in vitro and in vivo. Biomed Res Int. 2016;2016:9604257.

[37] Li Z, Wang J, Wang Z, Xu Y. Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions. EBioMedicine. 2023;92:104601.

[38] Zhao J, Zhu Y, Fu Q, Zhu Y, Zhao G. HEATR1 promotes proliferation in gastric cancer in vitro and in vivo. Acta Biochim Biophys Sin. 2020;52(9):1030-1039.

[39] Chen W, Shi K, Liu J, et al. Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer. Bioact Mater. 2023;23:1-15.

[40] Ando H, Fukushima M, Eshima K, et al. A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model. Cancer Med. 2019;8(17):7313-7321.

[41] Kang W, Maher L, Michaud M, et al. Development of a novel Orthotopic gastric cancer mouse model. Biol Proced Online. 2021;23(1):1.

[42] Busuttil RA, Liu DS, Di Costanzo N, Schröder J, Mitchell C, Boussioutas A. An orthotopic mouse model of gastric cancer invasion and metastasis. Sci Rep. 2018;8(1):825.

[43] Poh AR, O'Donoghue RJ, Ernst M, Putoczki TL. Mouse models for gastric cancer: matching models to biological questions. J Gastroenterol Hepatol. 2016;31(7):1257-1272.

[44] Kahounová Z, Pícková M, Drápela S, et al. Circulating tumor cell-derived preclinical models: current status and future perspectives. Cell Death Dis. 2023;14(8):530.

[45] Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206.

[46] Zhang T, Zhang L, Fan S, et al. Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity. PLoS One. 2015;10(7):e0134493.

[47] Chen Z, Huang W, Tian T, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. 2018;11(1):20.

[48] Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.

[49] Li F, Yu J, Pan T, et al. BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C-MYC/PLCG1/Perk Axis. Adv Sc. 2023;10(34):e2303091.

[50] Li Y, Fan Y, Xu J, et al. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma. J Exp Clin Cancer Res. 2022;41(1):257.

[51] Yue X, Petersen F, Shu Y, et al. Transfer of PBMC from SSc patients induces autoantibodies and systemic inflammation in Rag2^−/−/IL2rg^−/− mice. Front Immunol. 2021;12:677970.

[52] Koo GC, Hasan A, O'Reilly RJ. Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev Vaccines. 2009;8(1):113-120.

[53] Billerbeck E, Mommersteeg MC, Shlomai A, et al. Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol. 2016;65(2):334-343.

[54] Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 2006;108(2):487-492.

[55] André MC, Erbacher A, Gille C, et al. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells. J Immunol (Baltimore, Md.: 1950). 2010;185(5):2710-2720.

[56] Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364-372.

[57] Saito Y, Ellegast JM, Rafiei A, et al. Peripheral blood CD34(+) cells efficiently engraft human cytokine knock-in mice. Blood. 2016;128(14):1829-1833.

[58] Ito R, Takahashi T, Katano I, et al. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol (Baltimore, Md.: 1950). 2013;191(6):2890-2899.

[59] Zhu M, Zhang P, Yu S, et al. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. J Exp Clin Cancer Res. 2022;41(1):14.

[60] Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 2019;8(8):889.

[61] Cui JX, Xu XH, He T, et al. L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis. J Exp Clin Cancer Res. 2023;42(1):52.

[62] Jiang H, Shi Z, Wang P, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409-418.

[63] O'Brien NA, McDermott MSJ, Zhang J, et al. Development of a novel CLDN18.2-directed monoclonal antibody and antibody-drug conjugate for treatment of CLDN18.2-positive cancers. Mol Cancer Ther. 2023;22(12):1365-1375.

[64] Chen J, Liao S, Xiao Z, et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. Front Immunol. 2022;13:1007579.

[65] Chuprin J, Buettner H, Seedhom MO, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20(3):192-206.

[66] Corso S, Isella C, Bellomo SE, et al. A comprehensive PDX gastric cancer collection captures cancer cell-intrinsic transcriptional MSI traits. Cancer Res. 2019;79(22):5884-5896.

[67] Hulton CH, Costa EA, Shah NS, et al. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nat Can. 2020;1(3):359-369.

[68] Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1):4.

[69] Shi J, Li Y, Jia R, Fan X. The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer. 2020;146(8):2078-2088.

[70] Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013.

[71] Zeng M, Pi C, Li K, et al. Patient-derived xenograft: a more standard“Avatar” model in preclinical studies of gastric cancer. Front Oncol. 2022;12:898563.

[72] Jin KT, Du WL, Lan HR, et al. Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review. Cancer Sci. 2021;112(7):2592-2606.

[73] Arrieta MC, Walter J, Finlay BB. Human microbiota-associated mice: a model with challenges. Cell Host Microbe. 2016;19(5):575-578.

[74] Schoental R. Carcinogenic activity of N-methyl-N-nitroso-N′-nitroguanidine. Nature. 1966;209(5024):726-727.

[75] Gunes-Bayir A, Guler EM, Bilgin MG, Ergun IS, Kocyigit A, Dadak A. Anti-inflammatory and antioxidant effects of carvacrol on N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) induced gastric carcinogenesis in Wistar rats. Nutrients. 2022;14(14):2848.

[76] Sethi NS, Kikuchi O, Duronio GN, et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020;52(2):219-230.

[77] Miao ZF, Sun JX, Adkins-Threats M, et al. DDIT4 licenses only healthy cells to proliferate during injury-induced metaplasia. Gastroenterology. 2021;160(1):260-271.e10.

[78] Chen YX, He LL, Xiang XP, Shen J, Qi HY. O(6)-methylguanine DNA methyltransferase is upregulated in malignant transformation of gastric epithelial cells via its gene promoter DNA hypomethylation. World J Gastroint Oncol. 2022;14(3):664-677.

[79] Yamachika T, Nakanishi H, Inada K, et al. N-methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn J Cancer Res. 1998;89(4):385-391.

[80] Yamamoto M, Furihata C, Ogiu T, et al. Independent variation in susceptibilities of six different mouse strains to induction of pepsinogen-altered pyloric glands and gastric tumor intestinalization by N-methyl-N-nitrosourea. Cancer Lett. 2002;179(2):121-132.

[81] Ji L, Qian W, Gui L, et al. Blockade of β-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res. 2020;80(10):2004-2016.

[82] Ohgaki H, Fukuda M, Tohma Y, et al. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinog. 2000;28(2):97-101.

[83] Sakamoto K, Hikiba Y, Nakagawa H, et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology. 2010;139(1):226-238.e6.

[84] Tomita H, Yamada Y, Oyama T, et al. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res. 2007;67(9):4079-4087.

[85] Choi B, Yu J, Han TS, et al. Gastric carcinogenesis in the miR-222/221 transgenic mouse model. Cancer Res Treat. 2017;49(1):150-160.

[86] Tsubura A, Lai YC, Miki H, et al. Review: animal models of N-methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. In Vivo (Athens, Greece). 2011;25(1):11-22.

[87] Bessède E, Mégraud F. Microbiota and gastric cancer. Semin Cancer Biol. 2022;86(Pt 3):11-17.

[88] Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology. 1990;99(5):1315-1323.

[89] Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 1997;112(4):1386-1397.

[90] Druffner SR, Venkateshwaraprabu S, Khadka S, et al. Comparison of gastric inflammation and metaplasia induced by Helicobacter pylori or Helicobacter felis colonization in mice. Microbiol Spectr. 2024;12:e0001524.

[91] Arnold IC, Lee JY, Amieva MR, et al. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology. 2011;140(1):199-209.

[92] Danon SJ, O'Rourke JL, Moss ND, Lee A. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. Gastroenterology. 1995;108(5):1386-1395.

[93] Court M, Robinson PA, Dixon MF, Crabtree JE. Gastric Helicobacter species infection in murine and gerbil models: comparative analysis of effects of H. pylori and H. felis on gastric epithelial cell proliferation. J Infect Dis. 2002;186(9):1348-1352.

[94] Li N, Xu X, Zhan Y, et al. YAP and β-catenin cooperate to drive H. pylori-induced gastric tumorigenesis. Gut Microbes. 2023;15(1):2192501.

[95] Sierra JC, Asim M, Verriere TG, et al. Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut. 2018;67(7):1247-1260.

[96] Gobert AP, Asim M, Smith TM, et al. The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori. Biomed Pharmacother. 2023;158:114092.

[97] Lemos LM, Miyajima F, Castilho GR, Martins DT, Pritchard DM, Burkitt MD. Hexane extracts of Calophyllum brasiliense inhibit the development of gastric preneoplasia in Helicobacter felis infected INS-gas mice. Front Pharmacol. 2017;8:92.

[98] Park JM, Han YM, Park YJ, Hahm KB. Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis. J Clin Biochem Nutr. 2021;68(1):37-50.

[99] Song H, Lv X, Yang J, et al. A novel chimeric flagellum fused with the multi-epitope vaccine CTB-UE prevents Helicobacter pylori-induced gastric cancer in a BALB/c mouse model. Appl Microbiol Biotechnol. 2015;99(22):9495-9502.

[100] Su T, Li F, Guan J, et al. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling. Phytomedicine. 2019;63:152968.

[101] Chen ZM, Hu J, Xu YM, et al. Cryptotanshinone inhibits cytotoxin-associated gene A-associated development of gastric cancer and mucosal erosions. World J Gastrointest Oncol. 2021;13(7):693-705.

[102] Jeong M, Park JM, Han YM, et al. Dietary intervention of artemisia and green tea extracts to rejuvenate Helicobacter pylori-associated chronic atrophic gastritis and to prevent tumorigenesis. Helicobacter. 2016;21(1):40-59.

[103] Hong X, Li H, Lin Y, et al. Efficacy and potential therapeutic mechanism of Weiwei decoction on spasmolytic polypeptide-expressing metaplasia in Helicobacter pylori-infected and Atp4a-knockout mice. J Ethnopharmacol. 2024;319(Pt 1):117062.

[104] Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2015;359(2):345-351.

[105] Arnold IC, Zigova Z, Holden M, et al. Comparative whole genome sequence analysis of the carcinogenic bacterial model pathogen Helicobacter felis. Genome Biol Evol. 2011;3:302-308.

[106] Smet A, Flahou B, Mukhopadhya I, et al. The other Helicobacters. Helicobacter. 2011;16(Suppl 1):70-75.

[107] Dyer V, Brüggemann H, Sörensen M, et al. Genomic features of the Helicobacter pylori strain PMSS1 and its virulence attributes as deduced from its in vivo colonisation patterns. Mol Microbiol. 2018;110(5):761-776.

[108] Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. Gastroenterology. 2010;138(4):1455-1467, 1467.e1-4.

[109] Lee JY, Kim N, Choi YJ, et al. Histologic findings and inflammatory reactions after long-term colonization of Helicobacter felis in C57BL/6 mice. J Cancer Prev. 2014;19(3):224-230.

[110] Nam KT, Hahm KB, Oh SY, et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res. 2004;10(23):8105-8113.

[111] Hahm KB, Kim DH, Lee KM, et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003;18(Suppl 1):24-38.

[112] Lee JY, Kim N, Choi YJ, et al. Effect of N-methyl-N-Nitrosourea on Helicobacter-induced gastric carcinogenesis in C57BL/6 mice. J Cancer Prev. 2016;21(3):182-186.

[113] Han SU, Kim YB, Joo HJ, et al. Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. J Gastroenterol Hepatol. 2002;17(3):253-261.

[114] Maruta F, Sugiyama A, Ishida K, et al. Timing of N-methyl-N-nitrosourea administration affects gastric carcinogenesis in Mongolian gerbils infected with Helicobacter pylori. Cancer Lett. 2000;160(1):99-105.

[115] Hayakawa Y, Fox JG, Gonda T, Worthley DL, Muthupalani S, Wang TC. Mouse models of gastric cancer. Cancer. 2013;5(1):92-130.

[116] Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest. 1996;98(8):1918-1929.

[117] Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140(1):210-220.

[118] Tebbutt NC, Giraud AS, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 2002;8(10):1089-1097.

[119] Ding L, Li Q, Chakrabarti J, et al. MiR130b from Schlafen4(+) MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer. Gut. 2020;69(10):1750-1761.

[120] Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011;6:95-119.

[121] Feng Z, He X, Zhang X, et al. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat Cancer. 2022;3(5):581-594.

[122] Lin W, Zhang Y, Yang Y, et al. Anti-PD-1/Her2 bispecific antibody IBI315 enhances the treatment effect of Her2-positive gastric cancer through Gasdermin B-cleavage induced Pyroptosis. Adv Sci. 2023;10(30):e2303908.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.